Menu Search
Equities

Shanghai Junshi Biosciences Co Ltd

688180:SHH

Shanghai Junshi Biosciences Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)23.65
  • Today's Change-0.82 / -3.35%
  • Shares traded3.49m
  • 1 Year change-36.71%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Junshi Biosciences Co Ltd grew revenues 3.38% from 1.45bn to 1.50bn while net income improved from a loss of 2.39bn to a smaller loss of 2.28bn.
Gross margin67.77%
Net profit margin-129.54%
Operating margin-121.74%
Return on assets-18.42%
Return on equity-25.80%
Return on investment-23.01%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Shanghai Junshi Biosciences Co Ltd fell by 2.22bn. Cash Flow from Financing totalled 711.83m or 47.37% of revenues. In addition the company used 2.00bn for operations while cash used for investing totalled 933.19m.
Cash flow per share--
Price/Cash flow per share--
Book value per share6.58
Tangible book value per share6.04
More ▼

Balance sheet in CNYView more

Shanghai Junshi Biosciences Co Ltd has a Debt to Total Capital ratio of 28.01%, a higher figure than the previous year's 11.39%.
Current ratio2.11
Quick ratio1.87
Total debt/total equity0.3966
Total debt/total capital0.2801
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.